{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:21:40Z","timestamp":1791872500361,"version":"4.3.4"},"reference-count":24,"publisher":"The Journal of Food and Drug Analysis (JFDA), Food and Drug Administration, Taiwan (TFDA)","issue":"4","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,14]],"date-time":"2016-07-14T00:00:00Z","timestamp":1468454400000},"content-version":"vor","delay-in-days":956,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jfda-online.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Food and Drug Analysis"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.jfda.2013.09.037","type":"journal-article","created":{"date-parts":[[2013,10,23]],"date-time":"2013-10-23T16:46:21Z","timestamp":1382546781000},"page":"S69-S72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"S","title":["Medication-assisted treatment for opioid addiction: Methadone and buprenorphine"],"prefix":"10.38212","volume":"21","author":[{"given":"Andrew J.","family":"Saxon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yih-Ing","family":"Hser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Woody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"25385","reference":[{"key":"10.1016\/j.jfda.2013.09.037_bib1","first-page":"404","article-title":"When \u201cenough\u201d is not enough: new perspectives on optimal methadone maintenance dose","volume":"67","author":"Leavitt","year":"2000","journal-title":"Mt Sinai J Med"},{"key":"10.1016\/j.jfda.2013.09.037_bib2","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.phrs.2004.05.002","article-title":"Methadone\u2013metabolism, pharmacokinetics and interactions","volume":"50","author":"Ferrari","year":"2004","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jfda.2013.09.037_bib3","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/cpt1972135part1633","article-title":"The levels of methadone in the plasma in methadone maintenance","volume":"13","author":"Inturrisi","year":"1972","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jfda.2013.09.037_bib4","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00003088-200241140-00003","article-title":"Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence","volume":"41","author":"Eap","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jfda.2013.09.037_bib5","first-page":"1347","article-title":"The involvement of cytochrome P450 3A4 in the N-demethylation of L-alpha-acetylmethadol (LAAM), norLAAM, and methadone","volume":"5","author":"Moody","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jfda.2013.09.037_bib6","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/00004714-200104000-00016","article-title":"Cytochrome P450 2D6 genotype and methadone steady-state concentrations","volume":"21","author":"Eap","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.jfda.2013.09.037_bib7","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/jama.281.11.1000","article-title":"Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial","volume":"281","author":"Strain","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jfda.2013.09.037_bib8","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0376-8716(03)00056-5","article-title":"The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic","volume":"70","author":"Walsh","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jfda.2013.09.037_bib9","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S0376-8716(03)00060-7","article-title":"Buprenorphine: how to use it right","volume":"70","author":"Johnson","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jfda.2013.09.037_bib10","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/clpt.1994.71","article-title":"Clinical pharmacology of buprenorphine: ceiling effects at high doses","volume":"55","author":"Walsh","year":"1994","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jfda.2013.09.037_bib11","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/bja\/aei145","article-title":"Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats","volume":"94","author":"Dahan","year":"2005","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.jfda.2013.09.037_bib12","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1360-0443.2009.02843.x","article-title":"Abuse liability of intravenous buprenorphine\/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers","volume":"105","author":"Comer","year":"2010","journal-title":"Addiction"},{"key":"10.1016\/j.jfda.2013.09.037_bib13","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1001\/jama.2010.1427","article-title":"Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial","volume":"304","author":"Ling","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.jfda.2013.09.037_bib14","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S0376-8716(03)00058-9","article-title":"Pharmacokinetics of the combination tablet of buprenorphine and naloxone","volume":"70","author":"Chiang","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jfda.2013.09.037_bib15","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1177\/00912709922008236","article-title":"Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations","volume":"39","author":"Nath","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jfda.2013.09.037_bib16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.drugalcdep.2005.08.005","article-title":"Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine","volume":"82","author":"Compton","year":"2006","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jfda.2013.09.037_bib17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.drugalcdep.2003.11.008","article-title":"Relative bioavailability of different buprenorphine formulations under chronic dosing conditions","volume":"74","author":"Strain","year":"2004","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jfda.2013.09.037_bib18","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/sj.npp.1300251","article-title":"Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers","volume":"28","author":"Greenwald","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jfda.2013.09.037_bib19","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00003088-200544070-00001","article-title":"Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence","volume":"44","author":"Elkader","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jfda.2013.09.037_bib20","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/BF02246290","article-title":"Effects of buprenorphine and methadone in methadone-maintained subjects","volume":"119","author":"Walsh","year":"1995","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jfda.2013.09.037_bib21","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0140-6736(03)12600-1","article-title":"1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial","volume":"361","author":"Kakko","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jfda.2013.09.037_bib22","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0376-8716(81)90096-X","article-title":"The Swedish methadone maintenance program: a controlled study","volume":"7","author":"Gunne","year":"1981","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jfda.2013.09.037_bib23","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.drugalcdep.2012.08.002","article-title":"Buprenorphine\/naloxone and methadone effects on laboratory indices of liver health: a randomized trial","volume":"128","author":"Saxon","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jfda.2013.09.037_bib24","doi-asserted-by":"crossref","unstructured":"Hser YI, Saxon AJ, Huang DY, et\u00a0al. Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial. Addiction. In Press.","DOI":"10.1111\/add.12333"}],"container-title":["Journal of Food and Drug Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1021949813001014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1021949813001014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1021949813001014?httpAccept=text\/plain","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T14:16:02Z","timestamp":1666620962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1021949813001014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S1021949813001014"],"URL":"https:\/\/doi.org\/10.1016\/j.jfda.2013.09.037","relation":{},"ISSN":["1021-9498"],"issn-type":[{"value":"1021-9498","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medication-assisted treatment for opioid addiction: Methadone and buprenorphine","name":"articletitle","label":"Article Title"},{"value":"Journal of Food and Drug Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfda.2013.09.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}